TrialBlood cancer journal2021

KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma.

Sundar Jagannath et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.